CN1891220A - 2－氨基－3－烷基嘧啶酮衍生物在制备药物中的用途 - Google Patents

2－氨基－3－烷基嘧啶酮衍生物在制备药物中的用途 Download PDF

Info

Publication number: CN1891220A
Authority: CN; China
Prior art keywords: amino; pyridin; methyl; pyrimidin; alkyl
Prior art date: 2000-03-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CNA2006100061354A

Other languages

English (en)

Chinese (zh)

Inventor

A·阿尔马里奥加西亚

R·安多

K·阿里托莫

J·R·弗罗斯特

A·T·李

A·索达

F·厄哈拉

K·瓦塔纳贝

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sanofi Aventis France

Tanabe Pharma Corp

Original Assignee

Sanofi Aventis France

Mitsubishi Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-23

Filing date

2001-03-22

Publication date

2007-01-10

2001-03-22 Application filed by Sanofi Aventis France, Mitsubishi Pharma Corp filed Critical Sanofi Aventis France

2007-01-10 Publication of CN1891220A publication Critical patent/CN1891220A/zh

Status Pending legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Obesity (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

CNA2006100061354A 2000-03-23 2001-03-22 2－氨基－3－烷基嘧啶酮衍生物在制备药物中的用途 Pending CN1891220A (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00400800.9		2000-03-23
EP00400800A EP1136482A1 (en)	2000-03-23	2000-03-23	2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CNB018069916A Division CN1247567C (zh)	2000-03-23	2001-03-22	2－氨基－3－烷基嘧啶酮衍生物作为GSK3β抑制剂

Publications (1)

Publication Number	Publication Date
CN1891220A true CN1891220A (zh)	2007-01-10

Family

ID=8173604

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CNA2006100061354A Pending CN1891220A (zh)	2000-03-23	2001-03-22	2－氨基－3－烷基嘧啶酮衍生物在制备药物中的用途
CNB018069916A Expired - Fee Related CN1247567C (zh)	2000-03-23	2001-03-22	2－氨基－3－烷基嘧啶酮衍生物作为GSK3β抑制剂

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CNB018069916A Expired - Fee Related CN1247567C (zh)	2000-03-23	2001-03-22	2－氨基－3－烷基嘧啶酮衍生物作为GSK3β抑制剂

Country Status (16)

Country	Link
US (2)	US6844335B2 (es)
EP (2)	EP1136482A1 (es)
JP (1)	JP4778657B2 (es)
KR (1)	KR100820543B1 (es)
CN (2)	CN1891220A (es)
AR (1)	AR028280A1 (es)
AT (1)	ATE380806T1 (es)
AU (1)	AU2001281487A1 (es)
CA (1)	CA2401241C (es)
CY (1)	CY1107236T1 (es)
DE (1)	DE60131844T2 (es)
DK (1)	DK1276738T3 (es)
ES (1)	ES2296783T3 (es)
PT (1)	PT1276738E (es)
SI (1)	SI1276738T1 (es)
WO (1)	WO2001070729A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI241298B (en)	1998-09-25	2005-10-11	Mitsubishi Chem Corp	Pyrimidone derivatives
EP1136482A1 (en) *	2000-03-23	2001-09-26	Sanofi-Synthelabo	2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
SE518184C2 (sv)	2000-03-31	2002-09-03	Perstorp Flooring Ab	Golvbeläggningsmaterial innefattande skivformiga golvelement vilka sammanfogas med hjälp av sammankopplingsorgan
CA2407013A1 (en)	2000-04-26	2002-10-22	Eisai Co., Ltd.	Pharmaceutical composition promoting defecation
DE60208051T2 (de)	2001-09-21	2006-06-22	Sanofi-Aventis	3-substituierte-4-pyrimidonderivate
IL160700A0 (en) *	2001-09-21	2004-08-31	Mitsubishi Pharma Corp	3-substituted-4-pyrimidone derivatives
TW201041580A (en) *	2001-09-27	2010-12-01	Alcon Inc	Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
TWI301834B (en) *	2001-10-22	2008-10-11	Eisai R&D Man Co Ltd	Pyrimidone compound and pharmaceutical composition including the same
TWI330183B (es)	2001-10-22	2010-09-11	Eisai R&D Man Co Ltd
EA009027B1 (ru) *	2002-12-16	2007-10-26	Мицубиси Фарма Корпорейшн	Производные 3-замещенного-4-пиримидона
EP1460076A1 (en) *	2003-03-21	2004-09-22	Sanofi-Synthelabo	Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
EP1460075A1 (en) *	2003-03-21	2004-09-22	Sanofi-Synthelabo	Substituted 8-Pyridinyl-6,7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 8-Phenyl-6-7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one derivatives
KR20050122220A (ko)	2003-03-25	2005-12-28	다케다 샌디에고, 인코포레이티드	디펩티딜 펩티다제 억제제
TWI357408B (en) *	2003-03-26	2012-02-01	Mitsubishi Tanabe Pharma Corp	3-substituted-4-pyrimidone derivatives
BRPI0413452A (pt) *	2003-08-13	2006-10-17	Takeda Pharmaceutical	composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
WO2005026148A1 (en)	2003-09-08	2005-03-24	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
JP2007520558A (ja) *	2004-02-04	2007-07-26	スミスクライン・ビーチャム・コーポレイション	キナーゼ阻害剤として有用なピリミジノン化合物
CN102079743B (zh)	2004-03-15	2020-08-25	武田药品工业株式会社	二肽基肽酶抑制剂
EP1768679B1 (en) *	2004-07-09	2012-08-22	Agency for Science, Technology and Research	Modulation of gsk-3beta and method of treating proliferative disorders
TW200621760A (en)	2004-09-09	2006-07-01	Mitsubishi Pharma Corp	2-morpholino-4-pyrimidone compound
EP1805164B9 (en) *	2004-09-29	2011-09-07	Mitsubishi Tanabe Pharma Corporation	6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors
WO2006068978A2 (en)	2004-12-21	2006-06-29	Takeda Pharmaceutial Company Limited	Dipeptidyl peptidase inhibitors
EP1885454A2 (en)	2005-05-04	2008-02-13	DeveloGen Aktiengesellschaft	Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
CA2620333A1 (en)	2005-08-26	2007-03-01	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation with sabcomelin
GEP20135838B (en)	2005-09-14	2013-06-10	Takeda Pharmaceutical	Dipeptidyl peptidase inhibitors usage at diabetes treatment
CA2622642C (en)	2005-09-16	2013-12-31	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
AU2006304787A1 (en)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en)	2005-10-31	2011-04-27	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
TW200813015A (en) *	2006-03-15	2008-03-16	Mitsubishi Pharma Corp	2-(cyclic amino)-pyrimidone derivatives
EP2021000A2 (en)	2006-05-09	2009-02-11	Braincells, Inc.	Neurogenesis by modulating angiotensin
MX2009001913A (es) *	2006-08-23	2009-03-06	Pfizer Prod Inc	Compuestos de pirimidona como inhibidores de gsk-3.
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
AR076014A1 (es) *	2009-04-02	2011-05-11	Sanofi Aventis	Derivados de 3- (1,4) oxazepan -4-pirimidona
EP2464639A1 (en)	2009-08-13	2012-06-20	Mitsubishi Tanabe Pharma Corporation	Pyrimidone derivatives used as tau protein kinase 1 inhibitors
EP2464632A1 (en)	2009-08-13	2012-06-20	Mitsubishi Tanabe Pharma Corporation	Pyrimidone derivatives used as tau protein kinase 1 inhibitors
US20170209488A1 (en)	2014-07-17	2017-07-27	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods for treating neuromuscular junction-related diseases
WO2016207366A1 (en)	2015-06-26	2016-12-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of viral infections
WO2018217766A1 (en)	2017-05-22	2018-11-29	Whitehead Institute For Biomedical Research	Kcc2 expression enhancing compounds and uses thereof
WO2025215108A1 (en) *	2024-04-10	2025-10-16	Universitat De Barcelona	DUAL G9A/GSK-3ß INHIBITORS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS4935631B1 (es)	1970-12-28	1974-09-25
JPS4935633B1 (es)	1970-12-30	1974-09-25
JPS559099B2 (es) *	1972-08-07	1980-03-07
JPS4935633A (es)	1972-08-09	1974-04-02
US4460589A (en) *	1980-10-03	1984-07-17	The Upjohn Company	Process for treating hypertension
TW229142B (es) *	1992-04-15	1994-09-01	Nissan Detrochem Corp
US6153618A (en) *	1996-10-11	2000-11-28	Chiron Corporation	Inhibitors of glycogen synthase 3 kinase
JP2002514195A (ja) *	1996-12-05	2002-05-14	アムジエン・インコーポレーテツド	置換ピリミジン化合物およびそれの使用
NZ335992A (en) *	1996-12-05	2001-09-28	Amgen Inc	Substituted pyrimidinone and pyridone compounds and methods of use
TWI241298B (en) *	1998-09-25	2005-10-11	Mitsubishi Chem Corp	Pyrimidone derivatives
EP1136482A1 (en) *	2000-03-23	2001-09-26	Sanofi-Synthelabo	2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors

2000
- 2000-03-23 EP EP00400800A patent/EP1136482A1/en not_active Withdrawn
2001
- 2001-03-22 JP JP2001568932A patent/JP4778657B2/ja not_active Expired - Fee Related
- 2001-03-22 KR KR1020027012431A patent/KR100820543B1/ko not_active Expired - Fee Related
- 2001-03-22 US US10/221,598 patent/US6844335B2/en not_active Expired - Fee Related
- 2001-03-22 WO PCT/EP2001/003640 patent/WO2001070729A1/en not_active Ceased
- 2001-03-22 AU AU2001281487A patent/AU2001281487A1/en not_active Abandoned
- 2001-03-22 CN CNA2006100061354A patent/CN1891220A/zh active Pending
- 2001-03-22 ES ES01959921T patent/ES2296783T3/es not_active Expired - Lifetime
- 2001-03-22 CA CA2401241A patent/CA2401241C/en not_active Expired - Fee Related
- 2001-03-22 SI SI200130806T patent/SI1276738T1/sl unknown
- 2001-03-22 DE DE60131844T patent/DE60131844T2/de not_active Expired - Lifetime
- 2001-03-22 DK DK01959921T patent/DK1276738T3/da active
- 2001-03-22 CN CNB018069916A patent/CN1247567C/zh not_active Expired - Fee Related
- 2001-03-22 EP EP01959921A patent/EP1276738B8/en not_active Expired - Lifetime
- 2001-03-22 AT AT01959921T patent/ATE380806T1/de active
- 2001-03-22 PT PT01959921T patent/PT1276738E/pt unknown
- 2001-03-23 AR ARP010101372A patent/AR028280A1/es active IP Right Grant
2005
- 2005-01-13 US US11/035,264 patent/US7378413B2/en not_active Expired - Fee Related
2008
- 2008-03-07 CY CY20081100270T patent/CY1107236T1/el unknown

Also Published As

Publication number	Publication date
CN1419552A (zh)	2003-05-21
PT1276738E (pt)	2008-02-28
WO2001070729A1 (en)	2001-09-27
CY1107236T1 (el)	2012-05-23
JP4778657B2 (ja)	2011-09-21
US20050130998A1 (en)	2005-06-16
AU2001281487A1 (en)	2001-10-03
ES2296783T3 (es)	2008-05-01
DE60131844T2 (de)	2008-11-27
EP1136482A1 (en)	2001-09-26
KR20020093848A (ko)	2002-12-16
US6844335B2 (en)	2005-01-18
CA2401241C (en)	2011-11-29
US7378413B2 (en)	2008-05-27
KR100820543B1 (ko)	2008-04-07
DE60131844D1 (de)	2008-01-24
EP1276738A1 (en)	2003-01-22
AR028280A1 (es)	2003-04-30
CN1247567C (zh)	2006-03-29
CA2401241A1 (en)	2001-09-27
US20030187004A1 (en)	2003-10-02
SI1276738T1 (sl)	2008-06-30
EP1276738B1 (en)	2007-12-12
JP2003528095A (ja)	2003-09-24
ATE380806T1 (de)	2007-12-15
DK1276738T3 (da)	2008-04-21
EP1276738B8 (en)	2008-02-20

Publication	Publication Date	Title
CN1247567C (zh)	2006-03-29	2－氨基－3－烷基嘧啶酮衍生物作为GSK3β抑制剂
CN1319950C (zh)	2007-06-06	3－取代的－4－嘧啶酮衍生物
CN1267432C (zh)	2006-08-02	2－吡啶基－6,7,8,9－四氢嘧啶并[1,2－a]嘧啶－4－酮和7－吡啶基－2,3－二氢咪唑并[1,2－a]嘧啶－5(1H)酮衍生物
JP5210172B2 (ja)	2013-06-12	腫瘍治療用のピリジアジノン誘導体
CN1305872C (zh)	2007-03-21	喹唑啉类化合物的制备方法
CN1247586C (zh)	2006-03-29	治疗神经退化性疾病的取代的2－嘧啶基－6,7,8,9－四氢嘧啶并[1,2－a]嘧啶－4－酮及7－嘧啶基－2,3－二氢咪唑并[1,2－a]嘧啶－5(1h)酮衍生物
CN1294131C (zh)	2007-01-10	新嘧啶化合物
CN1784408A (zh)	2006-06-07	8－取代的－6,7,8,9－四氢嘧啶并[1,2－a]嘧啶－4－酮衍生物
CN1247585C (zh)	2006-03-29	取代的2－吡啶基－6,7,8,9－四氢嘧啶并[1,2－a]嘧啶－4－酮及7－吡啶基－2,3－二氢咪唑并[1,2－a]嘧啶－5(1h)酮衍生物
CN1556804A (zh)	2004-12-22	3-取代的-4-嘧啶酮衍生物
CN1271355A (zh)	2000-10-25	杂环化合物和以其为有效成分的抗肿瘤剂
CN1777607A (zh)	2006-05-24	取代的8' －吡啶基－二氢螺－[环烷基]－嘧啶并[ 1 , 2－a ]嘧啶－6－酮和8' －嘧啶基－二氢螺－[环烷基 ]－嘧啶并[1 , 2－a ]嘧啶－6－酮衍生物
CN1823064A (zh)	2006-08-23	用于治疗与gsk3有关的病症的2－芳基氨基－嘧啶
CN1914208A (zh)	2007-02-14	取代的8′－嘧啶基－二氢螺－[环烷基胺]－嘧啶并[1,2－a]嘧啶－6－酮衍生物
CN1271349A (zh)	2000-10-25	取代的喹唑啉衍生物及其作为酪氨酸激酶抑制剂的用途
CN1646519A (zh)	2005-07-27	N－苯基－2－嘧啶－胺衍生物的n－氧化物
CN1784407A (zh)	2006-06-07	取代的8－全氟烷基－6,7,8,9－四氢嘧啶并[1,2－a]嘧啶－4－酮衍生物
CN1902193A (zh)	2007-01-24	可用作蛋白激酶抑制剂的喹喔啉
KR20070058586A (ko)	2007-06-08	2-모르폴리노-4-피리미돈 화합물
CN1827619A (zh)	2006-09-06	嘧啶－5－（1h）－酮衍生物
KR20100016528A (ko)	2010-02-12	신경퇴행성 질환의 치료를 위한 아릴아미드 피리미돈 유도체
CN1263746C (zh)	2006-07-12	哒嗪酮衍生物
CN1166833A (zh)	1997-12-03	嘧啶基吡唑衍生物
CN1726209A (zh)	2006-01-25	3－取代的－4－嘧啶酮衍生物
CN1247584C (zh)	2006-03-29	1－[烷基]、1－[(杂芳基)烷基]和1－[(芳基)烷基]－7－吡啶基－咪唑并[1,2－a]嘧啶－5(1H)－酮衍生物

Legal Events

Date	Code	Title
2007-01-10	C06	Publication
2007-01-10	PB01	Publication
2007-03-07	C10	Entry into substantive examination
2007-03-07	SE01	Entry into force of request for substantive examination
2008-09-03	C02	Deemed withdrawal of patent application after publication (patent law 2001)
2008-09-03	WD01	Invention patent application deemed withdrawn after publication